As most of the literature on this topic is retrospective, prospective evaluations of these differences in lung cancer epidemiology, biology, and treatment outcomes between men and women, particularly as they apply to clinical practice, are required. Screening for EGFR mutations is now warranted in women with lung cancer. Further studies evaluating the effects of growth factor receptors on lung cancer development and the impact HRT may have on lung cancer risk and mortality in women are needed.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Resp Med. 2009;3(6):627-634. © 2009
Cite this: Lung Cancer in Women: The Differences in Epidemiology, Biology and Treatment Outcomes - Medscape - Dec 01, 2009.